title: Antifungal susceptibility of Candida isolates at one institution.
abstract: Species distribution and antifungal susceptibility of Candida isolates at one institution were evaluated. Detection rates of fungi were examined for 5 years between 2007 and 2011. Sensitivities of fungi to amphotericin B, flucytosine, fluconazole, micafungin, itraconazole, and voriconazole were evaluated in blood culture-positive patients. A total of 3,832 fungal isolates were detected, including Candida albicans 66.5%, Candida glabrata 20.3%, Candida parapsilosis 6.2%, Candida tropicalis 5.5%, and others 1.5%. Candidemia was diagnosed in 131 patients, and C. albicans, C. parapsilosis, C. glabrata, C. tropicalis, and others were present in 42.0%, 27.5%, 16.0%, 8.4%, and 6.1% of these patients, respectively. Voriconazole had the lowest MIC90s against C. albicans and C. parapsilosis (0.015 and 0.25). Micafungin had a low MIC90 against C. glabrata and C. tropicalis. C. albicans was the most common fungus in patients with candidemia. Voriconazole and micafungin were effective against C. albicans. Amphotericin B was effective for C. parapsilosis, and micafungin showed good efficacy against C. glabrata and C. tropicalis.
authors.affiliation: National Cerebral and Cardiovascular Center.
authors.forename: Shinji
authors.initials: S
authors.lastname: Katsuragi
authors.forename: Makoto
authors.initials: M
authors.lastname: Sata
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Takekazu
authors.initials: T
authors.lastname: Miyoshi
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Reiko
authors.initials: R
authors.lastname: Neki
authors.forename: Chinami
authors.initials: C
authors.lastname: Horiuchi
authors.forename: Kaoru
authors.initials: K
authors.lastname: Yamanaka
authors.forename: Chizuko
authors.initials: C
authors.lastname: Kamiya
authors.forename: Naoko
authors.initials: N
authors.lastname: Iwanaga
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Ikeda
authors.forename: Jun
authors.initials: J
authors.lastname: Yoshimatsu
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification*; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification; D041221:Candida glabrata / Q000187:drug effects / Q000302:isolation & purification; D041022:Candida tropicalis / Q000187:drug effects / Q000302:isolation & purification; D058387:Candidemia / Q000382:microbiology*; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000494:pharmacology*; D015725:Fluconazole / Q000494:pharmacology*; D005437:Flucytosine / Q000494:pharmacology*; D006268:Health Facilities; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology*; D007564:Japan; D055666:Lipopeptides / Q000494:pharmacology*; D000077551:Micafungin; D013997:Time Factors; D065819:Voriconazole / Q000494:pharmacology*
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine; D065819:Voriconazole; D000077551:Micafungin